ACELYRIN

ACELYRIN is a biopharma company dedicated to accelerating the development and delivery of transformative medicines for patients. The company is exploring innovative approaches in immunology to make a clinically meaningful difference relative to standard care. ACELYRIN has completed enrollment in the izokibep Phase 3 trial for hidradenitis suppurativa and expects to complete enrollment in the Phase 2b/3 trial for uveitis soon. The company is actively investigating the potential of izokibep and lonigutamab in diseases where differentiated inhibition of validated targets may help address unmet patient needs. ACELYRIN’s pipeline includes izokibep, a small therapeutic protein inhibitor of interleukin-17A (IL-17A) designed to overcome the limitations of monoclonal antibodies, lonigutamab, a subcutaneously delivered anti-IGF-1R currently in a Phase 1 study for Thyroid Eye Disease, and SLRN-517, a fully human monoclonal antibody targeting a distinct epitope of c-KIT for conditions like chronic urticaria. The company is headquartered in Agoura Hills, CA, with an office in South San Francisco, CA, and is guided by values of courage, compassion, collaboration, innovation, and a sense of urgency. ACELYRIN’s corporate culture of ‘Courageous Caring’ places patients first and embraces the concept that collective effort surpasses individual contributions. The company leverages a global network across pharma, biotech, finance, and academia to access promising therapeutic programs and conducts a licensing and acquisition search process focused on platforms, programs, and products with compelling science or data. ACELYRIN has a growth financing commitment of over $0 billion and multiple clinical-stage programs investigating the potential of its therapies in various diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, uveitis, thyroid eye disease, chronic urticaria, prurigo nodularis, bullous pemphigoid, and eosinophilic esophagitis.